Skip to main content

Table 1 Descriptive data for 950 patients with early rheumatoid arthritis at time of inclusion and at 5-year follow-up a

From: Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study

Variables YORA (N= 475) LORA (N= 75) P-value
Age at onset, yr <58 ≥58  
Female, n (%) 357/475 (75.2) 292/475 (61.5)  
Disease duration (mo) 6.90 (3.42) 6.45 (3.20) <0.05
RF+, n (%) 354/466 (75.9) 349/468 (75.6) NS
ANA+, n (%) 91/377 (24.2) 69/352 (19.6) NS
ACPA+ n (%) 313/429 (72.9) 267/411 (64.9) <0.05
PTPN22 T variant, n (%) 155/405 (38.3) 106/381 (27.8) <0.01
HLA-SE, shared epitope, n (%) 237/405 (58.5) 219/381 (57.5) NS
ESR at T0, mm/h (n = 948) 26.0 (21.5) 34.3 (24.2) <0,001
CRP at T0 mg/L (n = 888) 18.3 (23.7) 23.0 (24.6) <0.01
DAS28 at T0, (n = 788) 4.5 (1.5) 4.8 (1.4) <0.01
AUC DAS28 (6 mo)b 24.5 (7.2) 25.9 (7.0) <0.01
AUC DAS28 (12 mo)b 44.8 (13.4) 47.7 (13.2) <0.01
AUC DAS28 (24 mo)b 84.2 (26.8) 89.0 (23.3) <0.05
HAQ at T0, (n = 796) 0.81 (0.6) 0.92 (0.6) <0.01
Tender joints at T0 (n = 811) 6.3 (5.6) 6.5 (5.7) NS
Swollen joints at T0, (n = 812) 6.8 (5.2) 7.3 (5.2) NS
VAS pain at T0 (mm), (n = 800) 43.5 (25.5) 43.4 (25.9) NS
VAS global at T0 (mm) (n = 800) 44.0 (25.8) 45.0 (25.5) NS
Smoker (ever) T0, n (%) 287/443 (64.8) 300/447 (67.1) NS
Ex-RA ≤ T5, n (%)c,d 13/344 (3.8) 14/313 (4.5) NS
Nodules ≤ T5, n (%)c 60/312 (19.2) 38/275 (13.8) 0.079
DMARDs within 3 mo after T0, n (%)c,e 325/346 (93.9) 267/311 (85.9) <0.001
DMARDs (ever) ≤T5, n (%)c 344/348 (98.9) 299/310 (96.5) <0.05
Methotrexate (ever) ≤T5, n (%)c 313/346 (90.5) 253/311 (81.4) <0.001
Biologics (ever) ≤T5, n (%)c 84/342 (24.6) 23/310 (7.4) <0.001
NSAID T0, n (%) 317/455 (69.7) 297/466 (63.7) 0.056
NSAID ever ≤T5, n (%)c 307/340 (90.3) 233/307 (75.9) <0.001
COX-2-inhibitors at T0, n (%) 48/459 (10.5) 64/468 (13.7) NS
COX-2-inhibitors (ever) ≤T5, n (%)c 95/342 (27.8) 83/309 (26.8) NS
Corticosteroids T0 to T5 (mo)c 20.3 (23.8) 24.7 (23.8) <0.01
Corticosteroids (ever) ≤T5 (%)c 230/346 (66.5) 233/309 (75.4) <0.01
Hypertension at T0, n (%) 56/471 (11.9) 199/474 (41.9) <0.001
DM at T0, n (%) 22/464 (4.7) 54/470 (11.5) <0.001
CVD before T0, n (%)f 17/471 (3.6) 93/474 (19.6) <0.001
CVD related comorbidity at T0, n (%)g 86/475 (18.1) 238/475 (50.1) <0.001
Larsen score 0 (mo) (n = 437) 5.3 (5.8) 8.5 (6.2) <0.001
Larsen score 24 (mo) (n = 381) 9.5 (9.1) 12.5 (8.2) <0.001
Erosions 0 mo, n (%) 85/212 (40.1) 105/192 (54.7) <0.01
Erosions 24 mo, n (%) 107/173 (61.8) 119/158 (75.3) <0.01
Δ Larsen score 0 to 24 mo ≥3, n (%) 103/207 ( 49.8) 97/173 ( 56.1) 0.131
  1. aACPA, Anticyclic citrullinated peptide/protein; ANA, Antinuclear antibody; AUC, Area under the curve; CVD, Cardiovascular disease; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; DM, Diabetes mellitus; DMARD, Disease-modifying antirheumatic drug; ESR, Erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LORA, Late-onset rheumatoid arthritis; NS, Not significant; NSAID, Nonsteroidal anti-inflammatory drug; PTPN22, Protein tyrosine phosphatase nonreceptor type 22; RA, Rheumatoid arthritis; RF, Rheumatoid factor; SD: Standard deviation; SE, Shared epitope; VAS, Visual Analogue Scale; YORA, Young-onset rheumatoid arthritis. bAUC for DAS28 at 6 months after inclusion, YORA/LORA (n = 367/343); AUC for DAS28 at 12 months after inclusion, YORA/LORA (n = 308/281); AUC for DAS28 at 24 months after inclusion, YORA/LORA (n = 231/199). cPatients followed for 5 years (n = 665). dCriteria used for severe extraarticular manifestations: pericarditis, pleuritis, interstitial lung disease, Felty’s syndrome, neuropathy, scleritis/episcleritis, glomerulonephritis, major cutaneous vasculitis and vasculitis involving other organs [42]. eDMARD treatment started within 3 months from baseline (T0). fCVD comorbidities as previously described in detail [41]. gCVD-related comorbidity at time of inclusion (T0): CVD, hypertension or DM present before T0.